As of October 2025, the U.S. stock market has navigated a volatile week with major indices such as the Nasdaq and S&P 500 recording solid gains, despite ongoing concerns about banking sector health and geopolitical tensions. In this dynamic environment, high growth tech stocks in the U.S. remain a focal point for investors seeking opportunities that align with robust innovation trends and potential resilience amid economic fluctuations.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| ADMA Biologics | 20.61% | 23.30% | ★★★★★☆ |
| Exelixis | 10.59% | 20.82% | ★★★★★☆ |
| Palantir Technologies | 25.11% | 31.65% | ★★★★★★ |
| Workday | 11.20% | 32.07% | ★★★★★☆ |
| Circle Internet Group | 27.59% | 82.06% | ★★★★★☆ |
| OS Therapies | 56.64% | 68.61% | ★★★★★☆ |
| Vanda Pharmaceuticals | 22.66% | 59.11% | ★★★★★☆ |
| Aldeyra Therapeutics | 42.92% | 73.80% | ★★★★★☆ |
| Zscaler | 15.74% | 40.36% | ★★★★★☆ |
| Gorilla Technology Group | 32.75% | 122.61% | ★★★★★☆ |
Click here to see the full list of 72 stocks from our US High Growth Tech and AI Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Neurocrine Biosciences (NBIX)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Neurocrine Biosciences, Inc. is engaged in the discovery, development, and marketing of pharmaceuticals targeting neurological, neuroendocrine, and neuropsychiatric disorders globally with a market cap of approximately $13.89 billion.
Operations: Neurocrine Biosciences focuses on the research, development, and commercialization of pharmaceuticals, generating $2.51 billion in revenue from these activities.
Neurocrine Biosciences, a key player in neuropsychiatric treatments, recently showcased robust clinical advancements. At the American Psychiatric Nurses Association conference, their INGREZZA capsules demonstrated significant improvement in tardive dyskinesia symptoms over 48 weeks. Furthermore, the appointment of Mike Sibley as Senior VP and GM underlines their strategic focus on expanding the neuropsychiatry franchise. These developments, coupled with an expected annual earnings growth of 23.8% and R&D expenses aligned with industry innovation trends, position Neurocrine to potentially outperform in its sector despite a competitive landscape marked by rapid technological advancements and regulatory challenges.
- Navigate through the intricacies of Neurocrine Biosciences with our comprehensive health report here.
Evaluate Neurocrine Biosciences' historical performance by accessing our past performance report.
DoubleVerify Holdings (DV)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: DoubleVerify Holdings, Inc. offers media effectiveness platforms globally, with a market capitalization of approximately $1.78 billion.
Operations: DoubleVerify generates revenue primarily from its data processing segment, which contributed $714.26 million. The company focuses on providing media effectiveness solutions in the U.S. and internationally.
DoubleVerify's recent expansion of its post-bid brand suitability measurement on Meta Threads underscores its commitment to enhancing ad transparency and effectiveness in dynamic social media environments. This move, part of a broader strategy to innovate within digital advertising verification, leverages proprietary AI technology that ensures high accuracy and comprehensive coverage across multiple platforms. With a reported 11.1% annual revenue growth and an anticipated 24.8% increase in earnings, DoubleVerify is reinforcing its market position by addressing critical needs for brand safety in online advertising—a sector where precision and reliability are paramount. This strategic direction not only aligns with current industry demands but also sets the stage for sustained growth amidst evolving digital landscapes.
- Click to explore a detailed breakdown of our findings in DoubleVerify Holdings' health report.
Gain insights into DoubleVerify Holdings' past trends and performance with our Past report.
Semrush Holdings (SEMR)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Semrush Holdings, Inc. provides an online visibility management SaaS platform across the United States, the United Kingdom, and internationally, with a market cap of $1.07 billion.
Operations: SEMrush generates revenue primarily from its software and programming segment, which accounts for $413.96 million. The company operates within the online visibility management sector, providing services that enhance digital marketing strategies across various regions.
Semrush Holdings has recently unveiled its Enterprise Site Intelligence, a robust solution aimed at enhancing site health and visibility in the AI-driven search landscape. This innovation is crucial as data reveals AI overviews now appear in 13% of Google searches, highlighting the growing influence of AI on search dynamics. Furthermore, Semrush's strategic C-suite appointments underscore its commitment to scaling operations and improving customer experiences globally. With an annual revenue growth forecast at 14.5% and earnings expected to surge by 104.3%, Semrush is positioning itself strongly within the competitive tech sector by focusing on comprehensive site monitoring and advanced analytics that cater to enterprise needs.
Summing It All Up
- Click through to start exploring the rest of the 69 US High Growth Tech and AI Stocks now.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if DoubleVerify Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com